PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with HypertriglyceridemiaReportar como inadecuado




PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

PPAR ResearchVolume 2015 2015, Article ID 924131, 8 pages

Research Article

Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Department of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Received 24 August 2015; Accepted 30 September 2015

Academic Editor: Nguan Soon Tan

Copyright © 2015 Xiaomeng Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α PPAR-α. We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hypertriglyceridemia. This study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia group A and 40 controls group B. Group A was treated with fenofibrate 200 mg-day for 8 weeks. Serum irisin and clinical characteristics were examined. Serum irisin was significantly higher in group A compared with group B versus  ng-ml, and correlated with body mass index , , fasting blood glucose , , total cholesterol , , and high-density lipoprotein cholesterol , . In multiple regression analysis after controlling for confounders, only fasting blood glucose , and high-density lipoprotein cholesterol , were independently related to serum irisin. After 8 weeks of fenofibrate treatment, serum irisin significantly decreased in group A compared with baseline versus  ng-ml, . Conclusively, fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia, indicating that PPAR-α agonists may protect against metabolic disorders by improving irisin resistance.





Autor: Xiaomeng Feng, Xia Gao, Yumei Jia, Heng Zhang, Qingrong Pan, Zhi Yao, Ning Yang, Jia Liu, Yuan Xu, Guang Wang, and Xinch

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados